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Fraunhofer Institute for Process Engineering and Packaging IVV, Freising, GermanyThe use of blood as a diagnostic medium is routine and widespread
medical practice, not only in providing indications of general health sta-
tus, but also in delivering information on individual diseases via speciﬁc
constituent biomarkers. Established diagnostic clinical chemistry assess-
ments on blood serum target non-volatile markers – many disease-
speciﬁc – that include enzymes, proteins, peptides, hormones ormetabo-
lites to aid in the diagnosis of organ dysfunction or systemic illnesses,
from hepatic, pancreatic, renal and heart conditions, to cardiovascular
and bone diseases, amongst others (Neumann, 2015). Besides the
patient's presenting symptoms, such blood tests often provide the ﬁrst
clues of ill-health and trigger further probativemeasures such as biopsies.
Despite the utility of blood-based biomarkers in disease diagnosis –
notwithstanding its current indispensability in most cases – it is invasive
(painful, to a degree) and requires considerable effort for the preparation
and analysis of a sample, often offsite. A prospective alternative to this
approach with the potential to provide point-of-care analysis and instant
results – as well as being non-invasive – is offered in the form of exhaled
breath gas analysis (Dweik and Amann, 2008).
Breath analysis is based on the hypothesis that the biochemical per-
turbations associated with an imbalance in the body generate by-
products that enter the systemic circulation, are volatilised when they
encounter the liquid–gas interface of the alveoli in the lungs, and conse-
quently are expelled from the body during exhalation (Beauchamp and
Pleil, 2015). Unlike most diagnostic target compounds in blood (or
urine), breath biomarkers are necessarily volatile in nature – with
some minor exceptions – in that they must transition from the liquid-
phase of the blood to the gas-phase of breath in order to be observed
in the latter. Despite the growing number of developments and discov-
eries in the ﬁeld in recent years, advancements in breath analysis are
largely hampered by the vast number (N800) of volatile organic com-
pounds (VOCs) found to be present in breath (de Lacy Costello et al.,
2014), notably with a high degree of commonality between illnesses
and conditions such that unique, disease-speciﬁc markers seem unat-
tainable. Indeed, potential breath biomarkers awaiting discovery inevi-
tably will be endogenous compounds that are merely generated and
excreted at sufﬁciently high concentrations to allow for their ‘unique’
detection (when typical levels are below instrumental detection limits)
or their signiﬁcant discrimination from steady-state (healthy) levels
(Spacek and Risby, 2013).DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.07.027.
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breath analysis to detect liver cirrhosis, which is an advanced stage of
hepatic ﬁbrosis that is caused by several conditions, primarily viral hep-
atitis and chronic alcohol abuse (Byass, 2014). Presently, the detection
of liver disease is commonlymade byblood tests targeting liver function
enzymes, with subsequent biopsy if test results indicate high levels.
Symptoms are often presented late in the course of the disease, which
considerably reduces the chances of survival. In terms of prevalence
and mortality rates, worldwide liver cirrhosis mortality was estimated
at just over one million in 2010 (~2% of the global total) (Mokdad
et al., 2014), it was listed as the twelfth leading cause of death in the
USA (almost 32,000 deaths, or 1.3% of total deaths) (Murphy et al.,
2013) and is on the rise in countries such as the UK, where its preva-
lence in terms of premature mortality increased substantially (by 65%)
between 1990 and 2010 (Murray et al.). Thus the need for diagnostic
tools that offer an early and individualised detection of liver cirrhosis
is clearly evident.
The exhaled breath of liver cirrhosis suffererswas investigated in the
ensuing study via a two-stage approach, with an initial discovery phase
to seek potential breath biomarkers associated with the disease that
was supplemented by a targeted phase to follow the identiﬁed markers
during recovery progression after hepatic transplantation. Three com-
pounds, namely methanol, 2-pentanone and limonene, correlated
with liver disease and function, with elevated levels in the exhaled
breath of cirrhotic patients compared to a healthy control group and a
decreasing post-surgery trend that corresponded to the functional com-
mencement of the transplanted organ. The data revealed a high diag-
nostic accuracy based on the area under the receiver operator
characteristic (ROC) curve, with a sensitivity of 97% and a speciﬁcity of
70%.
The study is unique, not only due to its complementary (two-stage)
approach, but because the cirrhosis-related breath volatiles discovered
are, contradictorily, by no means unique, yet appear to reﬂect the func-
tionality of the liver to a high degree. Most breath research focusses on
searching for biomarkers generated by the illness, but rather than attrib-
uting these compounds to a production in the diseased liver, the authors
hypothesise that their elevated concentrations in the breath of cirrhotic
patients represent an accumulation in the body due to a lack ofmetabolic
breakdown by the impaired liver. This very plausible explanation, which
is supported by considerations on the biochemistry and physicochemical
properties of these biomarkers, makes for a strong and compelling case
on the potential utility of breath analysis in diagnosing liver cirrhosis
and monitoring organ function after transplantation via these markers.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1031J.D. Beauchamp / EBioMedicine 2 (2015) 1030–1031Moreover, the authors propose a prospective pharmacokinetic-based test
for assessing liver function, whereby known quantities of limonene are
administered to a patient and its subsequent wash-out from the body is
monitored in breath. This latter approach has a realistic potential in join-
ing the handful of approved breath screening tests that have found their
way to routine clinical use, offering a positive outlook in tackling this
chronic disease. I, for one, will follow the developments with bated
breath.
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